A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Key Inclusion Criteria:

• Male or female at birth, aged 18-70 years, inclusive, at screening Diagnosed withSAD according to the Diagnostic and Statistical Manual of Mental Disorders, FifthEdition, Text Revision (DSM-5-TR), confirmed by a Mini-InternationalNeuropsychiatric Interview (MINI) version 7.0.2

• LSAS total score of ≥70

• CGI-S score of ≥4

Key Exclusion Criteria:

• Clinically predominant psychiatric diagnosis other than SAD per the MINI

• Any past/lifetime or current diagnosis of a neurocognitive disorder or psychoticdisorder, or any current diagnosis of posttraumatic stress disorder, obsessivecompulsive disorder, or bipolar disorder

• Reports moderately severe to severe symptoms of depression

• Frequent use of benzodiazepines within 90 days of screening

• Used prohibited medication or prohibited herbal or other supplements within 5 half-lives or 21 days prior to Day 1 and unwillingness to refrain from their use for theduration of the trial

• Recent suicidal ideation or behavior

• Current or recent moderate or severe substance use disorder as assessed by the MINI

• Is unwilling/unable to abstain from alcohol, marijuana, THC, CBD, and/or any otherpsychoactive substances (except for nicotine or caffeine) for the duration of thetrial, per Investigator judgment, and/or has a positive alcohol test or drug test atScreening or Day 1

• Clinically significant abnormal findings in safety assessments

• Has significant progressive disorders or unstable medical conditions Unable tocomply with the requirements of the study or, in the opinion of the Investigator orSponsor, is unsuitable for the study